Crossmark

Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial

Crossref DOI link: https://doi.org/10.1186/s12885-024-11829-2

Published Online: 2024-01-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Cheng-Yi

Bai, Ming-Hua

Shen, Jin-Wen

Sun, Quan-Quan

Feng, Yan-Ru

Chen, Qian-Ping

Mao, Wei

Ju, Hai-Xing

Zhu, Ji
Funding

Funding for this research was provided by:

The Key Research-Development Program of Zhejiang Province under Grant (2022C03015)
License Information

Text and Data Mining valid from 2024-01-10

Version of Record valid from 2024-01-10
More Information

Article History

Received: 11 August 2023

Accepted: 3 January 2024

First Online: 10 January 2024

Declarations

:

: This study is approved by the Medical Ethics Committee of Zhejiang Cancer Hospital in China. We will fully inform eligible patients about the purpose and procedures of this study. They will sign a written informed consent after deciding to participate in the study. The study complies with the principles of the Declaration of Helsinki.

: Not applicable. No patients level information in this manuscript.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below